Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.2
(8.81%)
SEK 0.2
(8.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -282.03 Million SEK | -74.17% |
| 2022 | -149.34 Million SEK | 0.99% |
| 2021 | -167.59 Million SEK | 23.37% |
| 2020 | -213.06 Million SEK | -39.05% |
| 2019 | -179.99 Million SEK | -2449.84% |
| 2018 | -7.04 Million SEK | 86.23% |
| 2017 | -40.72 Million SEK | -82.55% |
| 2016 | -24.53 Million SEK | -234.35% |
| 2015 | -10.1 Million SEK | -198.28% |
| 2014 | -2.51 Million SEK | -16.79% |
| 2013 | -2.1 Million SEK | -159782.09% |
| 2012 | -1318.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -80.17 Million SEK | -15.27% |
| 2024 Q2 | -63.66 Million SEK | 16.27% |
| 2024 Q3 | -37.42 Million SEK | 54.67% |
| 2023 Q3 | -89.71 Million SEK | -1.21% |
| 2023 Q4 | -65.96 Million SEK | 26.47% |
| 2023 Q2 | -88.64 Million SEK | -54.85% |
| 2023 FY | - SEK | -74.17% |
| 2023 Q1 | -57.24 Million SEK | -4.55% |
| 2022 Q2 | -32.4 Million SEK | 11.91% |
| 2022 Q4 | -54.75 Million SEK | -30.4% |
| 2022 FY | - SEK | 0.99% |
| 2022 Q1 | -36.78 Million SEK | -14.41% |
| 2022 Q3 | -41.99 Million SEK | -29.6% |
| 2021 Q2 | -58.41 Million SEK | -14.77% |
| 2021 Q1 | -50.89 Million SEK | 19.11% |
| 2021 FY | - SEK | 23.37% |
| 2021 Q4 | -32.14 Million SEK | 24.72% |
| 2021 Q3 | -42.7 Million SEK | 26.89% |
| 2020 Q2 | -53.19 Million SEK | -9.28% |
| 2020 FY | - SEK | -39.05% |
| 2020 Q4 | -62.92 Million SEK | -9.4% |
| 2020 Q3 | -57.51 Million SEK | -8.12% |
| 2020 Q1 | -48.68 Million SEK | 12.42% |
| 2019 Q2 | -43.98 Million SEK | -33.78% |
| 2019 Q3 | -32.12 Million SEK | 26.96% |
| 2019 Q4 | -55.58 Million SEK | -73.02% |
| 2019 FY | - SEK | -2449.84% |
| 2019 Q1 | -32.88 Million SEK | -2.4% |
| 2018 Q3 | 60.85 Million SEK | 291.87% |
| 2018 Q2 | -31.71 Million SEK | -277.77% |
| 2018 Q4 | -32.11 Million SEK | -152.77% |
| 2018 Q1 | -8.39 Million SEK | 56.71% |
| 2018 FY | - SEK | 86.23% |
| 2017 Q4 | -19.39 Million SEK | -119.37% |
| 2017 Q3 | -8.83 Million SEK | -28.43% |
| 2017 Q2 | -6.88 Million SEK | 11.75% |
| 2017 FY | - SEK | -82.55% |
| 2017 Q1 | -7.79 Million SEK | -1.51% |
| 2016 Q2 | -5.08 Million SEK | -30.82% |
| 2016 Q3 | -7.88 Million SEK | -54.92% |
| 2016 Q1 | -3.88 Million SEK | -322.35% |
| 2016 Q4 | -7.68 Million SEK | 2.53% |
| 2016 FY | - SEK | -234.35% |
| 2015 Q2 | -1.3 Million SEK | -20.36% |
| 2015 Q1 | -1.08 Million SEK | 15.91% |
| 2015 FY | - SEK | -198.28% |
| 2015 Q4 | -920.97 Thousand SEK | 77.44% |
| 2015 Q3 | -4.08 Million SEK | -213.58% |
| 2014 Q3 | -598.94 Thousand SEK | 0.0% |
| 2014 Q4 | -1.28 Million SEK | -114.8% |
| 2014 FY | - SEK | -16.79% |
| 2013 FY | - SEK | -159782.09% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | -542.634% |
| Amniotics AB (publ) | -27.14 Million SEK | -939.063% |
| BioArctic AB (publ) | 275.38 Million SEK | 202.413% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 23.32% |
| Camurus AB (publ) | 562.54 Million SEK | 150.135% |
| Cantargia AB (publ) | -284.31 Million SEK | 0.803% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1340.487% |
| CombiGene AB (publ) | -35.33 Million SEK | -698.145% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -100.235% |
| Genovis AB (publ.) | 64.57 Million SEK | 536.773% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -145.445% |
| Mendus AB (publ) | -97.84 Million SEK | -188.242% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -661.757% |
| Intervacc AB (publ) | -68.98 Million SEK | -308.862% |
| Kancera AB (publ) | -61.88 Million SEK | -355.708% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -953.03% |
| LIDDS AB (publ) | -39.67 Million SEK | -610.948% |
| Lipum AB (publ) | -37.11 Million SEK | -659.808% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -2230.081% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 998.08% |
| NextCell Pharma AB | -40.98 Million SEK | -588.135% |
| OncoZenge AB (publ) | 7.26 Million SEK | 3981.544% |
| Saniona AB (publ) | -69.69 Million SEK | -304.667% |
| Simris Alg AB (publ) | -22.36 Million SEK | -1161.159% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 11.161% |
| Xintela AB (publ) | -53.47 Million SEK | -427.45% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -66.083% |
| Ziccum AB (publ) | -20.34 Million SEK | -1286.457% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1883.773% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1550.811% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 14101750.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -18.694% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -13459.279% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -1999.866% |
| Corline Biomedical AB | -1.69 Million SEK | -16578.474% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -62.72% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -414.602% |
| Aptahem AB (publ) | -10 Million SEK | -2717.73% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2542.056% |
| Fluicell AB (publ) | -25.91 Million SEK | -988.342% |
| Biovica International AB (publ) | -119.5 Million SEK | -135.999% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -567.945% |
| AcouSort AB (publ) | -16.7 Million SEK | -1588.517% |
| Abliva AB (publ) | -93.6 Million SEK | -201.292% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 11.616% |
| 2cureX AB (publ) | -35.13 Million SEK | -702.69% |
| I-Tech AB | 30.34 Million SEK | 1029.422% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 60.53% |
| Cyxone AB (publ) | -20.41 Million SEK | -1281.567% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -175.28% |
| Biosergen AB | 228 Thousand SEK | 123798.684% |
| Nanologica AB (publ) | -62.11 Million SEK | -354.021% |
| SynAct Pharma AB | -222.7 Million SEK | -26.642% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -543.015% |
| BioInvent International AB (publ) | -312.7 Million SEK | 9.809% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 91250.986% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 671623.132% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -21.764% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -3100.382% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -159.799% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -2359.09% |